Rameda Pharmaceuticals
Ahmed Oraby is a pharmacist with extensive experience in various pharmaceutical and research roles. Currently serving as a Meta-Analysis and Systematic Review specialist at the Systematic Review and Meta-Analysis Studies Center (SYRMAN) since April 2023, Ahmed has developed strong skills in analyzing research literature and utilizing multiple academic databases. Concurrently, Ahmed works as a pharmacist at the main military medical warehouse, managing medical supplies in compliance with military regulations. With a background in internships at several pharmaceutical companies, including Rameda Pharmaceuticals and EVA Pharma, and leadership as a Campus Director for the Hult Prize Foundation, Ahmed demonstrates a commitment to public health and innovation. Additionally, ongoing participation in online courses through Coursera showcases a dedication to enhancing skills in writing, negotiation, and English. Ahmed holds a Bachelor's degree in Pharmacy from Ahram Canadian University.
This person is not in any teams
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.